智通财经网·2025-08-05 02:28Core Insights - The report from Open Source Securities highlights the significant investments by leading companies in the amylin molecule space, indicating a competitive landscape with promising early data on safety and weight loss efficacy [1][2] Group 1: Industry Developments - Major pharmaceutical companies like AbbVie and Roche are making substantial investments in amylin molecules, with AbbVie paying an upfront fee of $350 million and potential milestone payments of up to $1.875 billion for Gubra's amylin molecule [1] - Roche has entered a collaboration with Zealand Pharmaceuticals for the development of petrelintide, committing an upfront payment of $1.65 billion and milestone payments of up to $3.6 billion, sharing profits in the US and Europe [1] - Eli Lilly is also expanding its amylin-related molecule portfolio, including a new dual agonist DACRA molecule with a potential payment structure similar to its previous deals [1] Group 2: Product Performance - Early data for amylin single-agent therapies show excellent safety profiles and significant weight loss, with Eli Lilly's Eloralintide demonstrating a maximum weight loss of 11.3% at 12 weeks [2] - The gastrointestinal safety profile of Eloralintide is impressive, with adverse events like diarrhea, nausea, and vomiting occurring in less than 10% of patients [2] - Several amylin molecules in development have half-lives ranging from 10 to 19 days, supporting the potential for monthly dosing regimens [2] Group 3: Future Catalysts - The next 6-12 months are expected to be rich in data readouts for amylin pipelines, with major companies like Roche, Eli Lilly, and AstraZeneca set to release phase 2 trial data [3] - Novo Nordisk is anticipated to present phase 1 data for two new amylin molecules, while other companies like AbbVie/Gubra and Metsera are expected to provide 12-week data [3] - Companies such as Viking, Structure, and Jiuyuan Gene are recommended for monitoring due to their clinical trial progress in the amylin space [3]